The FY2025 (Dec) proxy of Standard Biotools names 22 peer companies for pay. Among Standard Biotools and these peers, CEO pay was 5th highest of 13 and total shareholder return was 11th highest of 13.
5th highest of 13in Standard Biotools and its pay peers, FY2025 (Dec) by CEO pay:
$2.4M$23.2M
11th highest of 13in Standard Biotools and its pay peers, FY2025 (Dec) by total shareholder return:
$7$495
Pay peer group, FY2025 (Dec) proxy
| Halozyme Therapeutics | ||
| Twist Bioscience | ||
| Mirum Pharmaceuticals | ||
| Adaptive Biotechnologies | ||
| Veracyte | ||
| CareDx | ||
| Castle Biosciences | ||
| 10x Genomics | ||
| Cytek Biosciences | ||
| Pacific Biosciences Of California | ||
| Orasure Technologies | ||
| Cryoport | ||
| Azenta | Not disclosed | Not disclosed |
| Deciphera Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Gingko Bioworks Holdings, Inc. | Not disclosed | Not disclosed |
| Guardant Health | Not disclosed | Not disclosed |
| Maravai Lifesciences Holdings | Not disclosed | Not disclosed |
| Mesa Laboratories Inc /Co/ | Not disclosed | Not disclosed |
| Neogenomics | Not disclosed | Not disclosed |
| Quanterix | Not disclosed | Not disclosed |
| Surmodics, Inc. | Not disclosed | Not disclosed |
| iRhythm Technologies, Inc. | Not disclosed | Not disclosed |
22 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.